Cargando…

Current and new antitumor necrosis factor agents in perspective

Detalles Bibliográficos
Autor principal:	Maini, Ravinder N
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2833459/ https://www.ncbi.nlm.nih.gov/pubmed/15228614 http://dx.doi.org/10.1186/ar994

Ejemplares similares

Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
por: Al Sulais, Eman, et al.
Publicado: (2020)

Interleukin-6: a new therapeutic target
por: Smolen, Josef S, et al.
Publicado: (2006)

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed
por: Feldmann, Marc, et al.
Publicado: (2020)

Long‐term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease
por: Shiga, Hisashi, et al.
Publicado: (2022)

Management Strategies of Acute Retinal Necrosis: Current Perspectives
por: Powell, Brittany, et al.
Publicado: (2020)

Radiation effects on antitumor immune responses: current perspectives and challenges
por: Walle, Thomas, et al.
Publicado: (2018)

Closing remarks
por: Maini, Ravinder N
Publicado: (2004)

Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naïve steroid-refractory ulcerative colitis patients
por: Kitayama, Moto, et al.
Publicado: (2020)

Chiral Flavonoids as Antitumor Agents
por: Pinto, Cláudia, et al.
Publicado: (2021)

Stem cell treatment for avascular necrosis of the femoral head: current perspectives
por: Houdek, Matthew T, et al.
Publicado: (2014)

Correction: Interleukin-6: a new therapeutic target
por: Smolen, Josef S, et al.
Publicado: (2006)

HBV Reactivation in Patients Treated with Antitumor Necrosis Factor-Alpha (TNF-α) Agents for Rheumatic and Dermatologic Conditions: A Systematic Review and Meta-Analysis
por: Cantini, Fabrizio, et al.
Publicado: (2014)

Broad-Spectrum Preclinical Antitumor Activity of Chrysin: Current Trends and Future Perspectives
por: Moghadam, Ebrahim Rahmani, et al.
Publicado: (2020)

Systemic use of tumor necrosis factor alpha as an anticancer agent
por: Roberts, Nicholas J., et al.
Publicado: (2011)

Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges
por: Li, Shu‐Jin, et al.
Publicado: (2021)

Salmonella as an Innovative Therapeutic Antitumor Agent
por: Chang, Wen-Wei, et al.
Publicado: (2014)

Stem Cells as New Agents for the Treatment of Infertility: Current and Future Perspectives and Challenges
por: Volarevic, Vladislav, et al.
Publicado: (2014)

Antitumor necrosis factor-α antibodies as a noveltherapy for hepatocellular carcinoma
por: Li, Wei, et al.
Publicado: (2018)

Lysosome Labilizers Potentiate the Antitumor Effects of Tumor Necrosis Factor‐α
por: Masegi, Tsukio, et al.
Publicado: (1993)

Current Perspectives on Aptamers as Diagnostic Tools and Therapeutic Agents
por: Kumar Kulabhusan, Prabir, et al.
Publicado: (2020)

Ginseng polysaccharides: Potential antitumor agents
por: Tao, Ruizhi, et al.
Publicado: (2023)

Indole Antitumor Agents in Nanotechnology Formulations: An Overview
por: Russo, Eleonora, et al.
Publicado: (2023)

Transcription Factor DLX5 As a New Target for Promising Antitumor Agents
por: Timakhov, R.A., et al.
Publicado: (2011)

Diarylureas: Repositioning from Antitumor to Antimicrobials or Multi-Target Agents against New Pandemics
por: Catalano, Alessia, et al.
Publicado: (2021)

Antitumor Necrosis Factor Agents to Treat Endoscopic Postoperative Recurrence of Crohn's Disease: A Nationwide Study With Propensity-Matched Score Analysis
por: Cañete, Fiorella, et al.
Publicado: (2020)

Biosensors for European Zoonotic Agents: A Current Portuguese Perspective
por: Miguéis, Samuel da Costa, et al.
Publicado: (2021)

Natural Products as Anticancer Agents: Current Status and Future Perspectives
por: Naeem, Abid, et al.
Publicado: (2022)

Current Knowledge and Future Perspectives on Mesenchymal Stem Cell-Derived Exosomes as a New Therapeutic Agent
por: Joo, Hyeon Su, et al.
Publicado: (2020)

Lymphoma Developing in a Patient With Long-term Antitumor Necrosis Factor Therapy
por: Fensterseifer, Giovana Serrão, et al.
Publicado: (2022)

Risk of Orthopedic Surgical Site Infections in Patients with Rheumatoid Arthritis Treated with Antitumor Necrosis Factor Alfa Therapy
por: da Cunha, Bernardo Matos, et al.
Publicado: (2012)

β-blockers: a novel class of antitumor agents
por: Ji, Yi, et al.
Publicado: (2012)

Strengths and Challenges of Secretory Ribonucleases as AntiTumor Agents
por: Castro, Jessica, et al.
Publicado: (2021)

Antitumor Applications of Photothermal Agents and Photothermal Synergistic Therapies
por: Li, Chaowei, et al.
Publicado: (2022)

Current Perspective in the Discovery of Anti-aging Agents from Natural Products
por: Ding, Ai-Jun, et al.
Publicado: (2017)

PSMA-Targeting Imaging and Theranostic Agents—Current Status and Future Perspective
por: Debnath, Sashi, et al.
Publicado: (2022)

Q Fever Risk in Patients Treated with Chronic Antitumor Necrosis Factor-Alpha Therapy
por: Hirsch, Julianna, et al.
Publicado: (2016)

Post-traumatic chronic seronegative monarthritis responding to antitumor necrosis factor-alpha therapy
por: Fairweather, Jamie, et al.
Publicado: (2018)

Current Perspectives of Biocontrol Agents for Management of Fusarium verticillioides and Its Fumonisin in Cereals—A Review
por: N, Deepa, et al.
Publicado: (2021)

New Organometallic Ru(II) Compounds with Lonidamine Motif as Antitumor Agents
por: Shutkov, Ilya A., et al.
Publicado: (2023)

Natural and Biomimetic Antitumor Pyrazoles, A Perspective
por: Santos, Nádia E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_c81jt5cv7hnjoiooc185u1cdup